Home › Research › Biomarkers
Plasma Neurofilament Light and p-tau181 and Risk of Psychosis in Parkinson’s Disease
Lucy L. Gibson, Thomas A. Pollak, Amanda Heslegrave, Abdul Hye, Lucia Batzu, Silvia Rota, Dhaval Trivedi, Timothy R. Nicholson et al.. Journal of Parkinson's Disease, 2022-07-08
Topic: Plasma and spinal-fluid biomarkers
Plain-language summary
Baseline plasma NfL was a significant predictor of psychotic symptoms longitudinally across the study adjusted for age, Hoehn and Yahr stage, duration of follow up, duration of disease, baseline levodopa and dopamine agonist medication, and baseline cognition: (OR 8.15 [95% CI 1.40–47.4], p = 0.020). There was no association between NfL concentration and the cumulative prevalence of affective symptoms. Plasma p-tau181 concentration was not associated with psychotic or affective symptoms. These findings suggest psychotic symptoms are associated with greater neurodegeneration in PD. Further studies are needed to explore NfL as a potential biomarker for psychosis in PD.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Gibson, L. L., Pollak, T. A., Heslegrave, A., Hye, A., Batzu, L., Rota, S., et al. (2022). Plasma Neurofilament Light and p-tau181 and Risk of Psychosis in Parkinson’s Disease. Journal of Parkinson's Disease. https://doi.org/10.3233/jpd-223182
Vancouver
Gibson LL, Pollak TA, Heslegrave A, Hye A, Batzu L, Rota S, et al. Plasma Neurofilament Light and p-tau181 and Risk of Psychosis in Parkinson’s Disease. Journal of Parkinson's Disease. 2022. doi:10.3233/jpd-223182.
BibTeX
@article{gibson2022-8f209bfc,
author = {Gibson, Lucy L. and Pollak, Thomas A. and Heslegrave, Amanda and Hye, Abdul and Batzu, Lucia and Rota, Silvia and Trivedi, Dhaval and Nicholson, Timothy R. and others},
title = {{Plasma Neurofilament Light and p-tau181 and Risk of Psychosis in Parkinson’s Disease}},
journal = {Journal of Parkinson's Disease},
year = {2022},
doi = {10.3233/jpd-223182},
url = {https://doi.org/10.3233/jpd-223182}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Baseline plasma NfL was a significant predictor of psychotic symptoms longitudinally across the study adjusted for age, Hoehn and Yahr stage, duration of follow up, duration of disease, baseline levodopa and dopamine agonist medication, and baseline cognition: (OR 8.15 [95% CI 1.40–47.4], p = 0.020).
- There was no association between NfL concentration and the cumulative prevalence of affective symptoms.
- Plasma p-tau181 concentration was not associated with psychotic or affective symptoms.
- These findings suggest psychotic symptoms are associated with greater neurodegeneration in PD.
- Further studies are needed to explore NfL as a potential biomarker for psychosis in PD.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Participants63
- Effect sizeOR 8.15
- Evidence strengthModerate
How this study scored 55/100
Published in a peer-reviewed journal. Scored zero for study design and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multicenter collaboration and free to read, so those were left out: it earned 31 of the 56 points we could judge it on, which is 55 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of Parkinson's Disease) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2022 — within 6 year(s) of the newest study here |
| Sample size | 1 / 4 | 63 participants |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 31 / 56 | Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 31 of the 56 points we could judge it on is 55 out of 100. |
| Total | 55 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Biomarkers from nearby years
Also in Biomarkers
136 studies in the library are filed under Biomarkers with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Biomarkers hub.